Chembio Diagnostics reported that data from a study evaluating the sensitivity and specificity of the company’s point-of-care Dual Path Platform (DPP) rapid test for syphilis was recently published online in Clinical Infectious Diseases.
The complete article, “A dual point-of-care test shows good performance in simultaneously detecting nontreponemal and treponemal antibodies in patients with syphilis—a multi-site evaluation study in China,” can be accessed online at cid.oxfordjournals.org/content/early/2012/10/29/cid.cis928.abstract.
DPP Syphilis Screen and Confirm is a dual nontreponemal and treponemal POC syphilis test that permits the simultaneous yet separate detection of both markers at the point of care.
The study authors concluded that DPP Syphilis Screen and Confirm demonstrated good sensitivity and specificity in detecting treponemal and nontreponemal antibodies in three kinds of blood specimens. The study was supported by a grant from the Rapid Syphilis Test Introduction Project.
Chembio Diagnostics, 631-924-1135